Autologous haematopoietic stem cell transplantation (autoHSCT) results in progressive loss of immunity to vaccine-preventable infections and immune reconstitution is delayed for up to 12 months following transplant. [1] [2] [3] International consensus guidelines recommend post-transplant vaccination commencing 6 months post autoHSCT. 1, 4 However, uptake and compliance with post-transplant vaccination are frequently poor, with only one-third of patients receiving vaccination according to the recommended schedules. 5, 6 A post-transplant vaccination service was established at the Peter MacCallum Cancer Centre (PMCC), a tertiary cancer centre in Victoria, Australia in March 2014 as part of a multidisciplinary effort to improve health service delivery and outcomes for autoHSCT recipients. This service was introduced following a period of organisation-wide multidisiciplinary stakeholder engagement and information campaign. This comprehensive service consisted of regular scheduled patient reviews with specialist nursing and medical staff, enabling face-to-face education regarding vaccination (rationale, benefit, risks and recommendations), infection prevention measures and travel health, and delivery of a vaccination schedule aligned with prevailing national and international guidelines. 1, 4, 7, 8 During a scheduled review, all recommended vaccines were delivered together during the visit except for the first review (at 6 months), in which recommended vaccines were administered over two scheduled visits.
Before this service, patients post autoHSCT were followed up by a haematology nurse coordinator to commence vaccination with subsequent follow-up self-directed through their primary care physicians or the transplant service. New national immunisation guidelines were introduced in March 2013, which recommended commencement of vaccination 6 months post transplant in line with the international guidelines. 1, 7 Before this, the recommended re-vaccination schedule commenced at 12 months post transplant. 8 Vaccination schedules based on prevailing guidelines are summarised in Table 1 . We evaluated the impact of this dedicated vaccination service on post-transplant vaccination uptake, and compliance with prevailing national guidelines for immunisation.
All patients who underwent autoHSCT between October 2011 and September 2014 at PMCC were evaluated and followed up until October 2016. Patients were retrospectively classified as 'preservice cohort' (October 2011-September 2013) and 'post-service cohort' (October 2013-September 2014), corresponding to the availability of the vaccination service during the post-autoHSCT setting. Uniform data were collated from clinical and pharmacy databases, including type and timing of vaccine/s, total number of cycles completed and reasons for non-compliance with guidelines.
Timing of vaccination was considered compliant with guidelines if delivered within 1 month of the recommended schedule. 7, 8 Patients were considered ineligible for commencement of vaccination if they developed progressive disease, a concurrent medical complication (for example, hospitalisation), commenced additional cancer therapy (allogeneic HSCT, rituximab) or died during the post-transplant period. Patients with no record of vaccination or no documented plan for vaccination administered in a primary care setting or another healthcare facility were considered lost to follow-up. Delivery of influenza vaccine was not evaluated in this study, due to the seasonal nature of vaccination and varied timing of availability of this vaccine across the study years.
Patient demographics, vaccination uptake and compliance in each cohort were compared using Fisher's exact test or rank-sum testing, as appropriate. Univariate and multivariate regression analysis of clinical variables that were associated with commencement of vaccination post transplantation was performed. All analyses were performed using Stata (version 13.0, StataCorp Inc., College Station, TX, USA) and P ⩽ 0.05 was deemed statistically significant. The study was reviewed and approved by the PMCC human research ethics committee (16/116 R).
Overall, 250 autoHSCT patients were evaluated across two cohorts. There were 173 patients before implementation of the vaccination service and 77 patients post implementation. There were no significant demographic differences (age, sex, underlying disease and number of transplants) between patients in each cohort. Characteristics of each cohort are summarised in Table 2. A hundred and thirty two and 65 patients were eligible to commence vaccination post transplantation in pre-service and post-service cohorts, respectively. Of 53 patients ineligible to commence vaccination across all cohorts, 31 patients (58.4%) had disease progression, 11 patients (20.8%) died while the remaining patients were receiving further cancer therapy.
Following implementation of the dedicated vaccination service, a significantly higher proportion of patients commenced vaccinations (post-service cohort vs pre-service, 98.5% vs 86.3%, P o0.01) among patients eligible for vaccination. In addition, completion of all recommended vaccination cycles was significantly higher in the post-service cohort compared to the pre-service cohort (48.4% vs 35.1%, P = 0.02) while the proportion of patients lost to follow-up was significantly lower (7.8% vs 33.3%, P o0.01). A significantly lower proportion of patients in the pre-service cohort commenced post-transplant vaccination on schedule, as recommended by prevailing guidelines compared to the post-service cohort (46.4% vs 81.0%, P o0.01). For the post-service cohort, the median time to commencement was 6.1 months (5.8-6.6 months). In the preservice cohort, the median time to commencement of vaccination was 12.4 months (interquartile range (IQR) 11-13.4 months) on the pre-2013 schedule (prevailing recommendations for commencement at 12 months) and 10.1 months (7.7-13.0 months) on the post-2013 schedule (prevailing recommendations for commencement at 6 months). For patients with documented completion of vaccination cycles, the median time for completion was significantly shorter in the post-service cohort at 24.7 months (23.9-26.3 months) compared to 26.8 months (24.7-29.5 months) in the pre-service cohort (P o0.01). Table 3 summarises compliance with vaccination guidelines for patients in each cohort.
Patient age, gender and number of previous HSCT were not significantly associated with commencement of vaccination on univariate analysis. These factors remained non-significant with multivariate regression.
Patients are at increased risk for a range of vaccine-preventable infections in the post-autoHSCT period and international guidelines suggest a program of revaccination to reduce risk for these infections. 1 Uptake of recommended vaccinations post HSCT is a challenge frequently encountered by transplant services. Although many transplant centres routinely recommend vaccination, only a minority of centres offer vaccination on-site with most relying on primary care physicians to administer recommended vaccines. 9 Weaknesses of such decentralised models for vaccination have previously been identified, including workload of primary care physicians, poor motivation of clinicians, lack of practice nurses, cost of vaccines and lack of patient recall systems. 10 Furthermore, the complexity of schedules and limited patient knowledge form additional barriers to compliance with post-autoHSCT vaccination in the primary care setting. 5, 11, 12 Before the implementation of our dedicated vaccination service, autoHSCT patients were followed up by a haematology nurse coordinator in the post-transplant period. Re-vaccination was commenced in 86% of instances, with 46% receiving the first vaccine cycle in line with the recommended schedule. Notably, this is a much higher uptake compared to other published reports (generally 20-30%), underscoring the significant role of dedicated nursing staff. 5, 6 However, with the lack of scheduled reviews for vaccinations, the proportion of patients completing the recommended vaccination schedule was only 35%, and over 30% of patients were lost to follow-up. This suggests that in addition to skilled staff, infrastructure (for example, dedicated clinic, bookings schedule) is required for an optimal service.
Introduction of new guidelines in 2013 may have impacted the time to commencement in the pre-service cohort with a lower proportion of patients receiving their vaccine on schedule (46.4% vs 81.0%, P o0.01). However, following introduction of the dedicated vaccination service, the proportion of eligible patients Timing of first cycle could not be ascertained for n = 1.
Letter to the Editor commencing vaccination (regardless of timing) was significantly greater (98.5% vs 86.3%, P o 0.01). With regular scheduled reviews, nearly 50% of patients post autoHSCT completed all the recommended vaccination cycles at a significantly optimal period of time (24.7 months vs 26.8 months, P o0.01) and the number of patients lost to follow-up diminished by two thirds. Our dedicated service improved compliance with national vaccination guidelines. In contrast, the reported impact of vaccination cards, phone and email reminders has been mixed. 11, 13 Limitations of our study include the retrospective design, limiting the ability to determine reasons for delayed vaccine administration. However, factors influencing other process measures such as non-commencement and non-completion were obtained and reported.
Patients who receive care from multiple specialists and receive little or no care from primary care providers (such as patients with cancer) have been identified as having low vaccine uptake and therefore would benefit from targeted vaccination programs. 14 We have demonstrated that implementation of a multidisciplinary service, including scheduled reviews for patient education and vaccination, can significantly increase vaccination uptake and completion of recommended vaccinations in autoHSCT recipients. Future studies to evaluate patient experiences, healthcare cost benefits and impact on incidence of vaccine-preventable disease are required.
